Skip to main content
. Author manuscript; available in PMC: 2020 Aug 18.
Published in final edited form as: N Engl J Med. 2018 Jul 5;379(1):64–73. doi: 10.1056/NEJMra1706169

Figure 1. Chimeric Antigen Receptor (CAR) T Cells Engrafting, Trafficking to Tumor, and Proliferating Extensively after Infusion.

Figure 1.

After infusion, CAR T cells leave the blood and travel to sites of tumor, where they identify and kill tumor cells. This can trigger extensive proliferation of CAR T cells and the release of tumor antigens, which activates the immune system to recruit non–CAR T cells, thus eliciitng further antitumor responses in a process known as cross priming.